GlassScriptPhysician profile
Paul Feldan
NPI 1063517860
$4,103.16
in general payments reported to CMS, 2019-2025
34 companies · $725 in 2025
The $725 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2020: $449 · 2021: $837 · 2022: $468 · 2023: $757 · 2024: $508 · 2025: $725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,990.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,990.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $650.71 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $547.20 | 2019-2024 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $413.98 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Abbvie INC. | $311.28 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $300.61 | 2019-2025 | Xifaxan |
| Sunovion Pharmaceuticals INC. | $286.08 | 2019-2021 | |
| Pfizer INC. | $233.36 | 2020-2025 | |
| Novo Nordisk INC | $188.97 | 2019-2025 | Wegovy |
| Otsuka America Pharmaceutical, INC. | $180.73 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $167.22 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Collegium Pharmaceutical, INC. | $98.84 | 2024-2025 | Belbuca, Xtampza |
| Eisai INC. | $92.54 | 2021-2022 | |
| Amgen INC. | $75.96 | 2020-2025 | Evenity, Krystexxa |
| Corcept Therapeutics | $60.39 | 2025 | Korlym |
| Idorsia Pharmaceuticals US INC | $56.89 | 2022-2023 | Quviviq |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $49.79 | 2022 | |
| Merck Sharp & Dohme LLC | $38.65 | 2020-2021 | |
| Globus Medical, INC. | $30.03 | 2025 | Senza |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $28.48 | 2023 | Rexulti |
| Allergan, INC. | $27.97 | 2020 | |
| Sanofi Pasteur INC. | $26.32 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $26.24 | 2021 | |
| Ucb, INC. | $25.84 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $22.62 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.23 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.52 | 2024 | |
| Teleflex LLC | $16.98 | 2024 | Urolift |
| Hologic Sales and Service, LLC | $16.58 | 2025 | Aptima |
| Sumitomo Pharma America, INC. | $16.55 | 2025 | Gemtesa |
| Lundbeck LLC | $16.44 | 2025 | Rexulti |
| Actelion Pharmaceuticals US, INC. | $15.82 | 2025 | Uptravi, Opsumit |
| Bausch Health US, LLC | $14.98 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.76 | 2022 | |
| Axsome Therapeutics, INC. | $13.60 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Feldan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.